Intrommune Therapeutics Shares Oral Mucosal Immunotherapy Updates at Key Events

NEW YORK, May 21, 2024 -- Intrommune Therapeutics, Inc., a biotechnology firm specializing in allergen immunotherapy, is excited to announce its participation in three significant industry events this May. Intrommune showcased its innovative Oral Mucosal Immunotherapy (OMIT) at the Citizens JMP Life Science Conference, the BioNJ BioPartnering Conference, and will have CEO Michael Nelson speak at the Annual Food Allergy Fund Summit.

On May 13th, the Intrommune team attended the Citizens JMP Life Science Conference in New York City. The highlight of their presentation was the discussion of their Phase 1 OMEGA clinical trial targeting adults with peanut allergies. The response was overwhelmingly positive from other industry participants, including executives and investors. The data presented revealed that OMIT, which delivers allergenic proteins via a specially formulated toothpaste, offers a safer and more convenient treatment option compared to current therapies available for food allergies.

The following day, Intrommune presented as an Emerging Company at the BioNJ BioPartnering Conference in Jersey City, NJ. This premier event in New Jersey featured some of the most promising new technologies in the biotech sector. Intrommune was honored to be among the select companies showcasing their innovations and connecting with key industry figures.

Later this week, Intrommune's CEO, Michael Nelson, will participate in a panel at the 2024 Food Allergy Fund Summit. The summit is a gathering of leading minds and influential voices in biotechnology, focusing on the latest advancements in food allergy research and treatment. Michael Nelson will join the "Key Innovations: Novel Platforms and Technology Companies CEOs" panel on May 23rd at 1:00 pm EDT.

The OMEGA Trial is a significant part of Intrommune's research efforts. This Phase 1 clinical study was a randomized, double-blind, placebo-controlled trial involving 32 adult participants with peanut allergies. Subjects were randomly assigned in a 3:1 ratio to receive either an escalating dose of INT301 or a placebo. The trial was conducted with blinding to the investigator, patients, and sponsor. The United States Food and Drug Administration approved amendments to the study protocol, allowing the determination of the maximally tolerated dose and the inclusion of a maintenance period with a double-blind, placebo-controlled oral food challenge at the conclusion of the trial.

Food allergies remain a critical area of unmet medical need, affecting over 220 million people globally, including around 33 million in the United States. Management typically involves avoiding allergenic foods, which can be challenging as these foods, particularly peanuts, are common in many products. Accidental exposure can lead to severe, potentially life-threatening reactions such as anaphylaxis.

Oral Mucosal Immunotherapy (OMIT) offers a novel approach by utilizing patented biochemical processes to stabilize and deliver allergenic proteins directly via toothpaste. This method allows allergenic proteins to be exposed to the immune-active areas of the oral cavity during tooth brushing, facilitating allergy desensitization. The success of immunotherapy depends on consistent exposure to the allergen, gradually reducing the patient's sensitivity. OMIT's targeted delivery and ease of use promote better adherence to the treatment regimen compared to other immunotherapy methods.

Intrommune Therapeutics is dedicated to enhancing and protecting the lives of individuals with food allergies. Their lead product, INT301, has undergone Phase 1 clinical trials, promising a safe, effective, and user-friendly therapy for peanut and other food allergies. The ongoing and future studies aim to solidify OMIT's position as a convenient treatment option for the millions affected by food allergies worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!